Under 63 O.S., Sections 1-533 and 1-534 the following rules and regulations are established concerning the screening of all infants born in Oklahoma for the disorders of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidoisis type I (MPS I) and pompe disease upon completion of laboratory validation studies, and establishment of short-term follow-up services, and approval by the Commissioner of Health. This chapter also establishes rules and regulations concerning pulse oximetry screening of all infants born at birthing facilities in Oklahoma for critical congenital heart disease (CCDH) to be performed by the birthing facility pursuant to 63 O.S. Section 1-550.5.

Amended at 9 Ok Reg 1475, eff 5-1-92

Amended at 21 Ok Reg 1286, eff 5-27-04

Amended at 25 Ok Reg 1151, eff 5-25-08

Amended at 25 Ok Reg 105, eff 10-2-07 (emergency)

Amended at 25 Ok Reg 1153, eff 5-25-08

Amended at 31 Ok Reg 1596, eff 9-12-14

Amended at 36 Ok Reg 1688, eff 9-13-19

Amended at 38 Ok Reg 2040, eff 9-11-21